Related Experiment Videos
Retard implantation tablets on a matrix base with Eudragit as a structural substance
Die Pharmazie
|April 1, 1982
Summary
This study developed implant-tablets using 7-hydroxyethyltheophylline and Eudragit RS 100 for sustained drug release. Adjusting drug concentration in these matrix tablets allows for controlled drug liberation for up to six days.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
Background:
- Developing effective drug delivery systems is crucial for therapeutic efficacy.
- Prolonged drug availability often requires sophisticated formulation strategies.
Purpose of the Study:
- To create and evaluate a model for sustained release of low-concentration drugs.
- To investigate the use of Eudragit RS 100 as a matrix for implantable drug delivery systems.
Main Methods:
- Formulation of implant-tablets using 7-hydroxyethyltheophylline as the model drug and Eudragit RS 100 as the matrix.
- Standardization of tablet size, weight, and hardness, with varying drug concentrations.
- Coating of tablets with liquid Eudragit RS 100.
- Statistical analysis of drug liberation rates.
Main Results:
- Successful development of implant-tablets enabling prolonged drug availability.
- Demonstrated correlation between drug concentration and liberation rate.
- Development of a predictive diagram for achieving desired drug release profiles up to 6 days.
Conclusions:
- Eudragit RS 100 is a viable matrix material for creating sustained-release implant-tablets.
- Drug concentration is a key parameter for controlling the release kinetics of low-concentration drugs.
- The developed model offers a predictable method for achieving targeted drug liberation durations.